Development of a spectroscopic assay for bifunctional ligand-protein conjugates based on copper

Nucl Med Biol. 2004 Aug;31(6):795-802. doi: 10.1016/j.nucmedbio.2004.04.004.

Abstract

A simple, non-radioactive method for the determination of ligand-to-protein ratio (L/P) for novel ligand-antibody conjugates has been developed based on an exchange equilibrium with the purple Cu(II) complex of arsenazo III. The method requires a UV/Vis spectrometer and has been verified for monoclonal antibody Herceptin conjugates of a variety of ligand modalities, including common macrocyclic compounds NOTA and TETA, and with a new bifunctional tachpyridine (1H-Pyrrole-1-butanamide,N-[4-[[(1alpha,3alpha,5alpha)-3,5-bis[(2-pyridinylmethyl)amino]cyclohexyl](2-pyridinylmethyl)amino]butyl]-2,5-dihydro-2,5-dioxo-(9CI)). The spectroscopically derived values for L/P were verified by titration of the ligand-antibody conjugate with 64Cu. In each case, the value obtained by UV/Vis spectroscopy matches that found by radiolabeling. The method is rapid, taking less than 30 minutes with each ligand in this study.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antibodies, Monoclonal / chemistry
  • Antibodies, Monoclonal, Humanized
  • Chromatography, Thin Layer
  • Copper / chemistry*
  • Copper Radioisotopes
  • Cyclohexylamines / chemistry*
  • Indicators and Reagents
  • Ligands
  • Maleimides / chemistry*
  • Proteins / chemistry*
  • Radiopharmaceuticals / chemistry*
  • Spectrophotometry, Ultraviolet
  • Trastuzumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Copper Radioisotopes
  • Cyclohexylamines
  • Indicators and Reagents
  • Ligands
  • Maleimides
  • N-(4-((3,5-bis((2-pyridinylmethyl)amino)cyclohexyl)(2-pyridinylmethyl)amino)butyl)-2,5-dihydro-2,5-dioxo-1H-pyrrole-1-butanamide
  • Proteins
  • Radiopharmaceuticals
  • Copper
  • Trastuzumab